EE9400151A - PEG- interferoon konjugaadid - Google Patents

PEG- interferoon konjugaadid

Info

Publication number
EE9400151A
EE9400151A EE9400151A EE9400151A EE9400151A EE 9400151 A EE9400151 A EE 9400151A EE 9400151 A EE9400151 A EE 9400151A EE 9400151 A EE9400151 A EE 9400151A EE 9400151 A EE9400151 A EE 9400151A
Authority
EE
Estonia
Prior art keywords
peg
conjugates
interferon conjugates
interferon
polyethylene glycol
Prior art date
Application number
EE9400151A
Other languages
English (en)
Estonian (et)
Inventor
Karasiewicz Robert
Nalin Carlo
Rosen Perry
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of EE9400151A publication Critical patent/EE9400151A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EE9400151A 1992-08-26 1994-11-22 PEG- interferoon konjugaadid EE9400151A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Publications (1)

Publication Number Publication Date
EE9400151A true EE9400151A (et) 1996-02-15

Family

ID=25467637

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400151A EE9400151A (et) 1992-08-26 1994-11-22 PEG- interferoon konjugaadid

Country Status (37)

Country Link
US (1) US5382657A (fr)
EP (1) EP0593868B1 (fr)
JP (1) JP2859105B2 (fr)
KR (1) KR100295520B1 (fr)
CN (3) CN1183112C (fr)
AT (1) ATE165102T1 (fr)
AU (1) AU668742B2 (fr)
BG (1) BG98067A (fr)
BR (1) BR9303469A (fr)
CA (1) CA2103829C (fr)
CZ (1) CZ169393A3 (fr)
DE (1) DE69317979T2 (fr)
DK (1) DK0593868T3 (fr)
EE (1) EE9400151A (fr)
ES (1) ES2116376T3 (fr)
FI (1) FI109765B (fr)
HR (1) HRP931094A2 (fr)
HU (1) HUT67013A (fr)
IL (1) IL106750A0 (fr)
IS (1) IS4067A (fr)
LT (1) LT3174B (fr)
LV (1) LV10907B (fr)
MW (1) MW7693A1 (fr)
MX (1) MX9305146A (fr)
MY (1) MY131445A (fr)
NO (1) NO933028D0 (fr)
NZ (2) NZ264872A (fr)
OA (1) OA09850A (fr)
PH (1) PH30460A (fr)
PL (1) PL300194A1 (fr)
RO (1) RO112730B1 (fr)
SI (1) SI9300423A (fr)
SK (1) SK89893A3 (fr)
UY (1) UY23635A1 (fr)
YU (1) YU56693A (fr)
ZA (1) ZA936098B (fr)
ZW (1) ZW11193A1 (fr)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DK1090645T3 (da) * 1994-02-08 2006-03-27 Amgen Inc Oral tilförsel af kemisk modificerede proteiner
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
CA2236591C (fr) 1995-11-02 2012-01-03 Schering Corporation Therapie par perfusion continue a faible dosage de cytokine
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2302834A1 (fr) * 1997-09-18 1999-03-25 F. Hoffmann-La Roche Ag Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
CA2312975C (fr) 1997-12-17 2012-08-21 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
SK285284B6 (sk) * 1998-03-26 2006-10-05 Schering Corporation Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
BR9910023A (pt) 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
ATE473759T1 (de) * 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
MXPA00012586A (es) * 1998-06-16 2004-05-21 Univ Oklahoma Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
CA2303992A1 (fr) 1999-04-08 2000-10-08 Schering Corporation Traitement des melanomes
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
ES2286029T3 (es) 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
WO2001005819A1 (fr) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Nouveaux composes conjugues a base de cyclosporine hydrosoluble
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6969524B1 (en) 1999-10-12 2005-11-29 Santen Pharamceutical Co., Ltd. Interferon complex and medicinal use thereof
IL149267A0 (en) * 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
EP1234035B1 (fr) 1999-12-03 2010-02-24 ZymoGenetics, Inc. Recepteur de cytokine humaine
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
EP1251866A1 (fr) * 2000-01-24 2002-10-30 Schering Corporation Combinaison de temozolomide et d'alpha-interferon pegyle pour le traitement du cancer
EP1908477A3 (fr) * 2000-01-24 2008-06-11 Schering Corporation Combinaison de témozolomide et interféron alpha pégylé pour le traitement du cancer
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US20040082765A1 (en) * 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
CA2428242A1 (fr) 2000-11-07 2002-05-16 Zymogenetics, Inc. Recepteur humain de facteur de necrose tumorale
CA2437989A1 (fr) * 2001-02-20 2002-08-29 Enzon, Inc. Lieurs polymeres a terminaisons ramifiees, et conjugues polymeres en contenant
WO2002066516A2 (fr) 2001-02-20 2002-08-29 Zymogenetics, Inc. Anticorps liant a la fois bcma et taci
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
JP2004532624A (ja) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド マウスサイトカイン受容体
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2002083166A1 (fr) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Complexes de polymeres d'interferons et leur utilisation medicinale
KR100976743B1 (ko) 2001-05-24 2010-08-19 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
WO2003000278A1 (fr) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Onguents
MD2053C2 (ro) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remediu cu acţiune interferonogenă
EP1419191B1 (fr) 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Procede de preparation rapide de polyethyleneglycols actives
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
KR100888371B1 (ko) 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DK1476181T3 (en) * 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
ES2291620T3 (es) * 2002-03-13 2008-03-01 Beijing Jiankai Technology Co., Ltd. Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior.
IL164214A0 (en) * 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer
CN1659274A (zh) 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
ATE503498T1 (de) 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004012773A1 (fr) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Additifs d'acides de polyalkyleneglycol
WO2004021993A2 (fr) * 2002-09-05 2004-03-18 The General Hospital Corporation Asialo-interferons modifies et utilisations correspondantes
CA2497772A1 (fr) * 2002-09-05 2004-03-18 The General Hospital Corporation Asialo-interferons et traitement du cancer du foie
WO2004028568A1 (fr) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugues de proteine de liaison du facteur de croissance insulinomimetique 4 et de poly (ethylene glycol)
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
MXPA05008785A (es) * 2003-02-19 2005-10-18 Pharmacia Corp Esteres de polietilen glicol activados.
CA2516552A1 (fr) * 2003-02-26 2004-09-10 Intermune, Inc. Preparations d'interferon modifie par du polyethylene glycol et leurs methodes d'utilisation
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (fr) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Analyse d'activite transcriptionnelle
EP1633317A4 (fr) 2003-05-16 2008-08-20 Intermune Inc Ligands des recepteurs des chimiokines synthetiques et leurs methodes d'utilisation
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EP1673387B1 (fr) 2003-10-10 2010-09-15 Novo Nordisk A/S Derives de il-21
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US20050089952A1 (en) * 2003-10-22 2005-04-28 Akzo Nobel N.V. Apparatuses and processes for increasing protein PEGylation reaction yields
WO2005040758A2 (fr) * 2003-10-24 2005-05-06 Intermune, Inc. Utilisation de pirfenidone dans des posologies therapeutiques
WO2005062949A2 (fr) * 2003-12-23 2005-07-14 Intermune, Inc. Methode permettant de traiter l'infection par un hepatovirus
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US8778880B2 (en) * 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2005123113A2 (fr) * 2004-06-14 2005-12-29 Intermune, Inc. Compositions d'interferons et leurs methodes d'utilisation
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CA2574564C (fr) 2004-07-29 2013-04-16 Zymogenetics, Inc. Utilisation des molecules il-28 et il-29 pour traiter le cancer et les troubles autoimmuns
CA2576549C (fr) 2004-08-12 2011-01-18 Schering Corporation Preparation stable d'interferon pegyle
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006071840A2 (fr) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle
EP2284191A3 (fr) 2004-12-22 2011-07-20 Ambrx, Inc. Procédé de préparation de hGH
WO2006068802A2 (fr) * 2004-12-22 2006-06-29 Ambrx, Inc. Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2006086396A2 (fr) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
ES2609429T3 (es) 2005-05-12 2017-04-20 Zymogenetics, Inc. Composiciones y métodos para modular respuestas inmunitarias
BRPI0609809A2 (pt) * 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
CA2609205A1 (fr) * 2005-06-03 2006-12-14 Ambrx, Inc. Molecules d'interferons humains ameliorees et utilisations de celles-ci
EP1893240A2 (fr) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Administration transmucosale de dérivés peptidiques
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101257925A (zh) * 2005-06-20 2008-09-03 派普根公司 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
WO2007000769A2 (fr) * 2005-06-29 2007-01-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Mutants d'interferon ?2 (ifn?2) de recombinaison
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
WO2007021297A1 (fr) * 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS D’ARNt ET LEURS UTILISATIONS
US20070238658A1 (en) 2005-09-28 2007-10-11 Levin Steven D IL-17A and IL-17F Antagonists and Methods of Using the Same
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
US20090018029A1 (en) * 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
ES2529065T3 (es) * 2005-12-14 2015-02-16 Ambrx, Inc. Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos
EP1985303B1 (fr) 2006-01-12 2012-11-21 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Composition pour administration orale contenant de l'Interferon-alpha
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007130453A2 (fr) * 2006-05-02 2007-11-15 Allozyne, Inc. Molécules substituées par des acides aminés
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
CN101336110B (zh) 2006-06-01 2011-06-01 程云 预防或治疗肝损伤的肽及其衍生物及其应用
CN1911447B (zh) * 2006-06-30 2010-05-12 复旦大学 转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
CA2666814A1 (fr) * 2006-08-21 2008-05-29 United Therapeutics Corporation Polytherapie destinee a traiter des infections virales
DK2064333T3 (da) * 2006-09-08 2014-05-05 Ambrx Inc Suppressor-trna-transkription i hvirveldyrceller
PT2061878E (pt) * 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
EP2121743B1 (fr) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
EP2076533B1 (fr) * 2007-05-02 2014-10-08 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
CA2707840A1 (fr) * 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
EP2186830B1 (fr) 2007-09-04 2012-03-07 Biosteed Gene Expression Tech. CO., LTD. Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
WO2009055343A2 (fr) 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
BRPI0822530B1 (pt) 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
PL2318029T3 (pl) * 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
CA2738033C (fr) * 2008-09-26 2019-11-26 Ambrx, Inc. Vaccins et micro-organismes dependant de la replication d'acide amine non naturels
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3025727A1 (fr) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Procédés de traitement des maladies du foie
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2437785B1 (fr) 2009-06-04 2015-02-25 Novartis AG Procédés d'identification de sites pour la conjugaison d'igg
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
WO2011143274A1 (fr) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptides inhibiteurs de vla4
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
WO2011159930A2 (fr) 2010-06-16 2011-12-22 Medtronic, Inc. Systèmes d'amortissement permettant de stabiliser des médicaments dans des dispositifs de distribution de médicaments
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP3572091B1 (fr) 2010-08-17 2023-12-13 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN105381450A (zh) 2010-11-30 2016-03-09 诺华有限公司 丙型肝炎病毒感染的新疗法
EP2481740B1 (fr) 2011-01-26 2015-11-04 DemeRx, Inc. Procédés et compositions pour préparer de la noribogaïne à partir de voacangine
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
RS53911B1 (sr) 2011-04-01 2015-08-31 Novartis Ag Tretman u infekciji virusom hepatitis b zasebno ili u kombinaciji sa hepatitis delta virusom i bolesti jetre koje ih prate
KR20140011379A (ko) 2011-04-13 2014-01-28 노파르티스 아게 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012158493A2 (fr) 2011-05-19 2012-11-22 Geysen Hendrik M Composés qui se lient au récepteur d'érythropoïétine
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
US20140314713A1 (en) 2011-07-20 2014-10-23 Universite Paris Diderot - Paris Vii Methods for determining treatment response in patients infected with hcv genotype 4
CN103228792A (zh) * 2011-08-25 2013-07-31 纳诺亘医药生物科技公司 PEG-干扰素λ1结合物
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2014528947A (ja) 2011-09-27 2014-10-30 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の治療のためのアリスポリビル
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
MY171759A (en) 2011-12-06 2019-10-28 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
CA2855994A1 (fr) 2011-12-09 2013-06-13 Demerx, Inc. Esters phosphoriques de noribogaine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
WO2013137869A1 (fr) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Polythérapie pour le traitement d'une infection par le hcv dans une population de patients co-infectés hcv-hiv
WO2013143581A1 (fr) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie pour le traitement d'une infection par le vhc dans une sous-population de sous-génotype de patients spécifique
WO2013149219A2 (fr) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Anticorps complètement humains qui se lient à vegfr2
WO2013177187A2 (fr) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Traitement de tumeur synergique avec du pk il-2 étendu et des agents thérapeutiques
WO2013174988A1 (fr) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction et de surveillance d'une réponse de traitement chez des sujets atteints du vhc et du vhc/vih
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
EP2863946A4 (fr) 2012-06-21 2016-04-13 Sorrento Therapeutics Inc Protéines de liaison à un antigène qui se lient à c-met
EP2864358B1 (fr) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Protéines de liaison à un antigène qui se lient à ccr2
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2014098877A1 (fr) 2012-12-20 2014-06-26 Demerx, Inc. Noribogaïne substituée
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (fr) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2728405T3 (es) 2014-05-01 2019-10-24 Eiger Biopharmaceuticals Inc Tratamiento de la infección por virus de hepatitis delta
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
CA2957717C (fr) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Traitement tumoral synergique a l'aide d'il-2 et d'une proteine de fusion fc liant l'integrine
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CA2958673A1 (fr) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Proteines de fixation antigenique fixant le cxcr3
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US11559567B2 (en) * 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
CN107532146A (zh) * 2015-03-17 2018-01-02 国立大学法人信州大学 通过使用ifn的非贴壁培养制备树突状细胞的方法
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
MX377531B (es) 2015-11-03 2025-03-10 Hoffmann La Roche Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
EP3858352A1 (fr) 2015-11-04 2021-08-04 Eiger Biopharmaceuticals, Inc. Traitement d'une infection par le virus de l'hépatite delta
CA3013051A1 (fr) 2016-01-29 2017-08-03 Heyue Zhou Proteines de liaison a l'antigene se liant a pd-l1
WO2018087345A1 (fr) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag Polythérapie comprenant un inhibiteur d'un antigène de hbsag, un analogue nucléosidique ou nucléotidique et un interféron
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (fr) 2017-01-10 2018-07-19 Nodus Therapeutics Polythérapie pour le traitment de tumeurs avec une protéine de fusion fc de liaison à l'intégrine et un modulateur immunitaire
JP7189399B2 (ja) 2017-01-18 2022-12-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2020032951A1 (fr) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Conjugués d'enzymes antipaludiques, kits les contenant, et procédés de production et d'utilisation associés
WO2019036605A2 (fr) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations
DK3849614T3 (da) 2018-09-11 2024-02-26 Ambrx Inc Interleukin-2-polypeptidkonjugater og anvendelser deraf
MX2021003435A (es) 2018-09-28 2021-06-15 Massachusetts Inst Technology Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
WO2020082057A1 (fr) 2018-10-19 2020-04-23 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-10, dimères de ceux-ci et leurs utilisations
WO2020154032A1 (fr) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Schéma posologique de dosage d'immunothérapie combinée pour un blocage de points de contrôle immunitaires
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
WO2021228983A1 (fr) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition pharmaceutique comprenant un composé à base d'arsenic, un inducteur d'ifn de type 1 et un inhibiteur de protéine kinase permettant de traiter le cancer
ES2929379T3 (es) 2020-05-20 2022-11-28 Inst Nat Sante Rech Med Métodos para el tratamiento de infecciones por coronavirus
US20210403908A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022043496A2 (fr) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cellules mait en tant que biomarqueurs et biocibles dans la covid-19
WO2022079205A1 (fr) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de polypeptides d'ifn-alpha pour le traitement d'infections à coronavirus
WO2022159414A1 (fr) 2021-01-22 2022-07-28 University Of Rochester Érythropoïétine pour un dysfonctionnement gastrointestinal
EP4313163A1 (fr) 2021-04-03 2024-02-07 Ambrx, Inc. Conjugués anticorps-médicament anti-her2 et leurs utilisations
EP4656202A1 (fr) 2023-02-09 2025-12-03 Xie, Yanhui Traitement de la dermatite atopique avec de l'interleukine 2 modifiée par du polyéthylène glycol, un glucocorticoïde et de l'acide hyaluronique
WO2025006676A2 (fr) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Compositions à base de protéines de liaison des facteurs de croissance de type insuline de type 1 (igfbpl1) et leurs procédés d'utilisation
WO2026043823A2 (fr) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non naturels spécifiques à un site, leurs procédés de préparation et leurs utilisations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (fr) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (fr) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (fr) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
JPS60127952A (ja) 1983-12-14 1985-07-08 Fanuc Ltd 領域加工方法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (fr) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
WO1990013540A1 (fr) * 1989-04-19 1990-11-15 Enzon, Inc. Carbonates actifs d'oxydes de polyalkylene pour la modification de polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
JP3187044B2 (ja) * 1989-12-01 2001-07-11 ビーエーエスエフ アクチェンゲゼルシャフト ヒルジン突然変異蛋白質及びヒルジンポリアルキレングリコール複合体
JPH04202293A (ja) * 1990-11-29 1992-07-23 Tonen Corp 作動油
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
SK89893A3 (en) 1994-04-06
AU668742B2 (en) 1996-05-16
CN1155618C (zh) 2004-06-30
BG98067A (en) 1994-12-02
JP2859105B2 (ja) 1999-02-17
YU56693A (sh) 1997-01-08
CN1088936A (zh) 1994-07-06
IS4067A (is) 1994-02-27
DK0593868T3 (da) 1999-02-08
CN1211578A (zh) 1999-03-24
ZA936098B (en) 1994-03-01
AU4478093A (en) 1994-03-03
CN1183112C (zh) 2005-01-05
BR9303469A (pt) 1994-03-22
CN1173500A (zh) 1998-02-18
DE69317979T2 (de) 1998-08-20
IL106750A0 (en) 1993-12-08
ES2116376T3 (es) 1998-07-16
RO112730B1 (ro) 1997-12-30
HUT67013A (en) 1995-01-30
CN1039015C (zh) 1998-07-08
ATE165102T1 (de) 1998-05-15
PL300194A1 (en) 1994-04-05
SI9300423A (en) 1994-03-31
EP0593868B1 (fr) 1998-04-15
FI109765B (fi) 2002-10-15
NZ248452A (en) 1995-12-21
FI933740L (fi) 1994-02-27
NZ264872A (en) 1996-01-26
LV10907A (lv) 1995-12-20
HRP931094A2 (en) 1997-06-30
LV10907B (en) 1996-04-20
LT3174B (en) 1995-02-27
DE69317979D1 (de) 1998-05-20
LTIP888A (lt) 1994-08-25
KR940003969A (ko) 1994-03-14
EP0593868A1 (fr) 1994-04-27
HU9302366D0 (en) 1993-11-29
OA09850A (fr) 1994-08-15
MX9305146A (es) 1994-03-31
KR100295520B1 (ko) 2001-09-17
MY131445A (en) 2007-08-30
US5382657A (en) 1995-01-17
CA2103829C (fr) 2003-04-08
JPH06192300A (ja) 1994-07-12
UY23635A1 (es) 1994-03-01
CA2103829A1 (fr) 1994-02-27
ZW11193A1 (en) 1994-03-23
FI933740A0 (fi) 1993-08-25
PH30460A (en) 1997-05-28
NO933028D0 (no) 1993-08-25
CZ169393A3 (en) 1994-04-13
MW7693A1 (en) 1994-06-08

Similar Documents

Publication Publication Date Title
DK0593868T3 (da) PEG-interferonkonjugater
FI971486L (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
TR26214A (tr) Baryum veya stronsiyum sulfid'in lavgalanma artiklarinin hazirlanmasi.
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
FI955524L (fi) Kiinteinä liuoksina olevia valmisteita
IT1206822B (it) Derivati di glicina in qualita' di agenti preventivi e terapeutici del le complicanze diabetiche
FI851365L (fi) Liposomer med inhalerbara allergener foer behandling av allergener, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
IT9019422A0 (it) Composizioni farmaceutiche ad attivita' depigmentante e "antiphotoaging"
MX9101393A (es) Uso de marcadores moleculares en la reproduccion de arboles
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона
ITMI910572A0 (it) Oligopeptidi eterociclici dotati di attivita' antitumorale
IT9048605A0 (it) Derivati della 1,2,3,4,-tetraidronaftilammina ad attivita' nootropica e composizioni farmaceutiche che li contengono.
IT9019970A0 (it) Composizioni farmaceutiche ad attivita' riduttrice di radicali ossigeno e loro preparazione
ITPD920214A1 (it) Formulazioni per promuovere l'assorbimento vaginale di polipeptidi
ES263015Y (es) "disposicion constructiva en la panelizacion de muebles y o elementos de mobiliario".
IT231883Y1 (it) pedana preposta alla pesca con la canna,in presenza di qualsiasi tipo di riva, aventi eccezionali doti di stabilita' e versatilita'
KR930017816U (ko) 유희용 다리
ITMI921950A0 (it) Composizioni farmaceutiche ad attivita' epato-trofica ed anti-aging
ITMI911714A1 (it) 2-ammino-4-aril-tiazoli ad attivita' antiasmatica e antiinfiammatoria delle vie aeree
ITMI920786A1 (it) 2-ammino-4-aril-tiazoli ad attivita' antiasmatica e antiinfiammatoria delle vie aeree
ITMI913485A1 (it) Scomposizione di un principio attivo in sue frazioni e le frazioni cosi' ottenute
KR950703574A (ko) 종양발생 진단에 있어서의 인터페론 조절 인자 1및 2(Interferon regulatory factors 1 and 2 in the diagnosis of tumorigenicity)
LV5177A3 (lv) Preparats "eridons" govju endometritu profilaksei un arstesanai
BR9004135A (pt) Jogo de mesa
IT9019701A1 (it) Sali ad attivita' antiinfiammatoria, antisettica, detergente e composizioni farmaceutiche